{"nctId":"NCT00819091","briefTitle":"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug","startDateStruct":{"date":"2008-12"},"conditions":["Diabetes Mellitus, Type 2"],"count":245,"armGroups":[{"label":"BI 1356","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: BI 1356"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"BI 1356","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nPatients between 18 and 80 years old with type 2 diabetes and insufficient glycemic control \\[glycosylated hemoglobin (HbA1c 7% to 10%)\\] despite therapy with a sulfonylurea drug\n\nExclusion criteria:\n\nMyocardial infarction,stroke or transient ischaemic attack in last 6 months Treatment with rosiglitazone, pioglitazone, GLP-1 analogues, insulin or anti-obesity drugs in the past 3 months Impaired hepatic function Severe renal impairment Current treatment with systemic steroids Change in thyroid hormone dosage Hereditary galactose intolerance","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18","description":"HbA1c is measured as a percent. The change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.10"},{"groupId":"OG001","value":"-0.54","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 18","description":"Change from baseline reflects the Week 18 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"4.5"},{"groupId":"OG001","value":"-8.2","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Absolute Efficacy Response (HbA1c < 7%) at Week 18","description":"An absolute efficacy response is defined as HbA1c \\< 7.0% at 18 weeks. A non-response is defined as HbA1c \\>= 7.0% at 18 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"15.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null},{"groupId":"OG001","value":"84.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Absolute Efficacy Response (HbA1c < 6.5%) at Week 18","description":"An absolute efficacy response is defined as HbA1c \\< 6.5% at 18 weeks. A non-response is defined as HbA1c \\>= 6.5% at 18 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"94.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c Lowering by at Least 0.5% From Baseline at Week 18","description":"An efficacy response is defined as HbA1c lowered by 0.5% or more at 18 weeks. A non-response is defined as HbA1c not lowered by 0.5% or more at 18 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"57.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.0","spread":null},{"groupId":"OG001","value":"42.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Mixed Model Repeated Measurements Analysis of Change From Baseline in HbA1c at Week 6","description":"HbA1c is measured as a percent. The change from baseline reflects the Week 6 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.07"},{"groupId":"OG001","value":"-0.43","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Mixed Model Repeated Measurements Analysis of Change From Baseline in HbA1c at Week 12","description":"HbA1c is measured as a percent. The change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.09"},{"groupId":"OG001","value":"-0.61","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Mixed Model Repeated Measurements Analysis of Change From Baseline in HbA1c at Week 18","description":"HbA1c is measured as a percent. The change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.10"},{"groupId":"OG001","value":"-0.55","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 6","description":"Change from baseline reflects the Week 6 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"3.8"},{"groupId":"OG001","value":"-13.5","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 12","description":"Change from baseline reflects the Week 12 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"4.7"},{"groupId":"OG001","value":"-10.3","spread":"3.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":84},"commonTop":["Hyperglycaemia"]}}}